Jazz Sues Amneal Over Xyrem Patents

Jazz Pharmaceuticals filed suit Sept. 17 in New Jersey, claiming Amneal Pharmaceuticals’ attempt to market a generic version of Xyrem (sodium oxybate) infringes patents covering the narcolepsy drug. According to the complaint, Amneal submitted an ANDA for the drug, infringing Jazz’s ‘988 and ‘203 patents. Amneal countered with a certification alleging Jazz’s patent claims are invalid and unenforceable, and attesting that the patents would not be infringed by the activities described in Amneal’s ANDA.
Generic Line